Featured Jobs – Boston Cambridge Biotech Networks

News Ticker

STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits

June 8, 2023 Comments Off on STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits

FDA Commissioner Robert Califf told a crowd of biotech leaders at the BIO convention that drug costs needed fixing. Click here to view original post… […]
Ameresco and Atura Power JV Selected to Build 250MW/1,000MWh Battery Energy Storage System

June 8, 2023 Comments Off on Ameresco and Atura Power JV Selected to Build 250MW/1,000MWh Battery Energy Storage System
Upstream Bio raises $200M in new financing round to get asthma drug to PhIII

June 8, 2023 Comments Off on Upstream Bio raises $200M in new financing round to get asthma drug to PhIII
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

June 8, 2023 Comments Off on Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
BIO speakers underscore ‘crucial’ moment for genetic medicines

June 8, 2023 Comments Off on BIO speakers underscore ‘crucial’ moment for genetic medicines

test

August 31, 2021 0

test
How spirituality can benefit medicine

March 30, 2022 Comments Off on How spirituality can benefit medicine
Exclusive: Following a severe setback, BridgeBio brings out the budget ax to chop staff but keeps quiet on the numbers

March 31, 2022 Comments Off on Exclusive: Following a severe setback, BridgeBio brings out the budget ax to chop staff but keeps quiet on the numbers
With pharma still struggling in Alzheimer’s, health tech companies want a swing

March 31, 2022 Comments Off on With pharma still struggling in Alzheimer’s, health tech companies want a swing
Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout

March 31, 2022 Comments Off on Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout

Nothing found